

More than 94 million adults in the United States live with high cholesterol, and thousands are affected by transthyretin amyloidosis (ATTR), a progressive and often underdiagnosed condition. Both significantly heighten the risk of cardiovascular disease—the leading cause of death worldwide. As science advances, a new frontier is emerging with the potential to transform how the cardiovascular community approaches these conditions: gene editing.

The *Advancing Gene Editing Therapy for Cardiovascular Disease* Heart House Roundtable convenes a diverse, multidisciplinary group of experts to explore the promise and challenges of gene editing in treating ATTR and hyperlipidemia. With technologies like CRISPR entering clinical trials and demonstrating early evidence of durable, one-time therapeutic effects, the landscape of cardiovascular care is poised for a paradigm shift. Gene editing holds promise for silencing or correcting disease-driving genes—such as *TTR* in ATTR and *PCSK9* in hyperlipidemia—offering alternatives to lifelong medication and mitigating progressive disease.

But with innovation comes complexity. Questions around safety, patient selection, affordability, regulation, and equitable access remain central to the responsible implementation of these technologies.

This virtual Roundtable will serve as a dynamic platform for critical conversations at the intersection of science, clinical application, ethics, and policy. Participants will discuss the latest advancements, assess clinical applications, and chart a course toward introducing gene editing into cardiovascular care safely, ethically, and equitably – for the benefit of patients now and in the future.

HEART HOUSE ROUNDTABLES

The Heart House Roundtables explore the practical issues that clinicians and patients face every day within high-value clinical areas. These meetings are grounded in the concept of convening a broad range of expertise to include representatives from professional societies, patients, federal agencies, integrated health systems, and others as identified.

Through interactive and in-depth discussions, participants not only identify and clarify gaps in clinical care, but also brainstorm potential solutions to help drive better patient care and outcomes.

Roundtables have historically been used to inform the development of actionable content to include clinical policy as well as clinician and patient tools to be used at the point of care.

For more information, visit [**ACC.org/ClinicalSolutions**](https://www.acc.org/ClinicalSolutions)